How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

34,964 results for

Plaque

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization. (PubMed)

Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization. Statins are widely used to lower cholesterol and to reduce cardiovascular events. Whether all statins have similar effects on plaque stabilization is unknown. We aimed to investigate coronary plaque response to treatment with different statins that result in similar lipid reduction using serial multimodality intracoronary imaging. Patients with de novo coronary artery disease requiring intervention were randomized (...) to rosuvastatin 10 mg (R10) or atorvastatin 20 mg (A20) daily. Optical coherence tomography and intravascular ultrasound were performed at baseline, 6 months, and 12 months. Untreated nonculprit plaques were analyzed by optical coherence tomography for thin-cap fibroatheroma, minimum fibrous cap thickness, lipid arc, and lipid length. Total and percent atheroma volume, respectively were analyzed by intravascular ultrasound. Forty-three patients completed the protocol (R10: 24 patients, 31 plaques; A20: 19

2019 American Journal of Cardiology

142. Small choroidal melanoma: detection with multimodal imaging and management with plaque radiotherapy or AU-011 nanoparticle therapy. (PubMed)

Small choroidal melanoma: detection with multimodal imaging and management with plaque radiotherapy or AU-011 nanoparticle therapy. To explore risk factors for choroidal nevus transformation into melanoma using multimodal imaging and review current treatment options.A recently published longitudinal study of 3806 choroidal nevi, imaged with optical coherence tomography (OCT), ultrasonography, and standard wavelength autofluorescence, revealed transformation into melanoma in 5.8% at 5 years (...) into melanoma was 1.1% for those with 0 risk factor, 11% with one factor, 22% with two factors, 34% with three factors, 51% with four factors, and 55% with five risk factors. Management of small choroidal melanoma typically involves plaque radiotherapy with 5 and 10-year rates of tumor recurrence at 7 and 11%, visual acuity loss (≥3 Snellen lines) at 39 and 49%, and melanoma-related metastasis at 4 and 9%. A novel infrared dye-conjugated virus-like nanoparticle (AU-011) is currently under investigation

2019 Current opinion in ophthalmology

143. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. (PubMed)

Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. Efficacy of tildrakizumab for plaque psoriasis was demonstrated in randomized, placebo-controlled trials.To consolidate tildrakizumab efficacy results by pooling data.Data (N = 2081) from tildrakizumab 100 mg, tildrakizumab 200 mg and placebo groups in three trials were pooled.Proportions of Psoriasis Area and Severity Index (PASI) 75 responders at week 12 (...) 12 PASI 75 responses vs. placebo with tildrakizumab 100 mg were similar between patients with (55.0%) or without (56.7%) prior biologics. PASI 90, PASI 100 and PGA responses were generally higher in patients without prior biologics. Week 8 PASI 50 response predicted PASI 90 response.Pooled data confirmed the efficacy of tildrakizumab for moderate-to-severe plaque psoriasis.© 2019 European Academy of Dermatology and Venereology.

2019 Journal of the European Academy of Dermatology and Venereology

144. Relationship of exercise to coronary artery disease extent, severity and plaque type: A coronary computed tomography angiography study. (PubMed)

Relationship of exercise to coronary artery disease extent, severity and plaque type: A coronary computed tomography angiography study. While exercise has been associated with favorable coronary artery disease (CAD) outcomes, the relationship between endurance exercise levels and CAD findings has not been well explored.To evaluate the relationship of endurance exercise to CAD findings by coronary computed tomographic angiography (CCTA).We evaluated consecutive patients referred to CCTA who (...) (>70%). CAD extent and severity was also summated CADRADS score, plaque burden by segment involvement score (SIS), and non-calcified plaque score (G-score). High-risk plaque (HRP), as defined by the presence of low attenuation plaque, positive arterial remodelling, spotty calcifications and napkin ring signs, was assessed. Finally, coronary artery calcium scores (CCS), as determined by Agatston units, were quantified.The study cohort comprised 252 patients (55.3y ±10.1, 39.7% females) with 97

2019 Journal of cardiovascular computed tomography

145. Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis. (PubMed)

Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis. Psoriasis is a chronic skin disorder that manifests as epidermal keratinocyte hyperplasia.We examined the effect of oxymatrine treatment on cell proliferation and apoptosis in skin lesions of psoriasis.Patients with severe plaque psoriasis were treated with oxymatrine or with acitretin. The skin lesions were stained with proliferating cell nuclear antigen (PCNA), Ki-67, Bcl-2, as well as examined

2019 British Journal of Dermatology

146. Helicobacter pylori infection combined with non-alcoholic fatty liver disease increase the risk of atherosclerosis: Focus in carotid artery plaque. (PubMed)

Helicobacter pylori infection combined with non-alcoholic fatty liver disease increase the risk of atherosclerosis: Focus in carotid artery plaque. Atherosclerosis has severe consequences on human health. Carotid artery plaques are a condition typically caused by atherosclerosis. Previous studies showed that nonalcoholic fatty liver disease (NAFLD) and Helicobacter pylori (H pylori) are risks factors for carotid artery plaque formation. We hypothesize that the combination of NAFLD with H pylori (...) infection increases the risk of carotid artery plaque formation.A total of 4669 subjects aged > 40 years who underwent routine health checkups between January 2006 and December 2015 were retrospectively reviewed. A serial examination, including abdominal ultrasound, carotid artery ultrasound and esophago-gastroduodenoscopy (EGD), and biopsy urease testing, was conducted.In total, 2402 subjects were enrolled. There were no differences in H pylori infection status among patients with or without NAFLD

2019 Medicine

147. Xylitol and sorbitol effects on the microbiome of saliva and plaque. (Full text)

Xylitol and sorbitol effects on the microbiome of saliva and plaque. Chewing gum containing xylitol may help prevent caries by reducing levels of mutans streptococci (MS) and lactobacilli in saliva and plaque. Very little is known about other species which are possibly beneficial to oral health. In this study, we employed high-throughput sequencing of the 16S rRNA gene to profile microbial communities of saliva and plaque following short-term consumption of xylitol and sorbitol containing (...) chewing gum. Participants (n = 30) underwent a washout period and were randomly assigned to one of two groups. Each group chewed either xylitol or sorbitol gum for three weeks, before undergoing a second four-week washout period after which they switched to the alternate gum for three weeks. Analysis of samples collected before and after each intervention identified distinct plaque and saliva microbial communities that altered dependent on the order in which gum treatments were given. Neither

2019 Journal of oral microbiology PubMed

148. Fractal dimension based carotid plaque characterization from three-dimensional ultrasound images. (PubMed)

Fractal dimension based carotid plaque characterization from three-dimensional ultrasound images. Irregularity of the plaque surface associated with previous plaque rupture plays an important role in the risk estimation of stroke caused by carotid atherosclerotic lesions. Thus, the aim of this study is to develop and validate novel vulnerability biomarkers from three-dimensional ultrasound (3DUS) images by analyzing the surface morphological characteristics of carotid plaque using fractal (...) geometry features. In the experiments, a total of 38 3DUS plaque images were obtained from two groups of patients treated with 80 mg of atorvastatin or placebo daily for 3 months respectively. Two types of 3D fractal dimensions (FDs) were used to describe the smoothness of plaque surface morphology and the roughness from intensity of 3DUS images. Student's t test showed that the two fractal features were effective for detecting the statin-related changes in carotid atherosclerosis with p < 0.00023

2019 Medical & biological engineering & computing

149. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin. (PubMed)

Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin. Although a recent clinical trial demonstrated that alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, significantly reduces the incidence of acute coronary events, the impact of alirocumab on plaque stabilization remains uncertain. The Efficacy of ALirocumab for Thin-cap (...) regarding the change in TCFA fibrous-cap thickness after 9 months of treatment.The outcomes of ALTAIR (ClinicalTrials.gov identifier: NCT03552432) will provide insights into the effect of alirocumab on plaque vulnerability following PCI in patients with suboptimal LDL-C control despite stable statin therapy.Copyright © 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

2019 Journal of cardiology

150. Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation. (PubMed)

Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation. The renin-angiotensin system plays an important role in promoting atherosclerotic plaque inflammation, which may be inhibited by angiotension-II receptor blockers.We investigated the effects of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation using 18 F-fluorodeoxyglucose (18 FDG) positron emission tomography (PET) imaging.Fifty patients with acute coronary syndrome (...) to a similar degree in both groups.Fimasartan and amlodipine reduce carotid atherosclerotic plaque inflammation similarly in patients with ACS, offering the same level of effectiveness.© 2018 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.

2019 Clinical cardiology

151. Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography. (PubMed)

Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography. The present study aimed to explore the efficacy of atorvastatin on patients with carotid plaque, applying superb microvascular imaging (SMI), and contrast-enhanced ultrasound (CEUS) for evaluating carotid intraplaque neovascularization.A total of 82 patients (82 carotid plaques) who were randomized into treatment group and control group underwent conventional ultrasound, CEUS, and SMI (...) with those in control group (P < .001). In treatment group, SMI-detected intraplaque neovascularization reduced from 69.23% to 48.72% while CEUS-detected ones reduced from 76.92% to 69.23%. By contrast, the percentage of intraplaque neovascularization in control group did not change too much either by SMI (65.12%, 67.44%) or CEUS (74.41%, 74.41%). The consistency between CEUS and SMI was above .75 at all assessments (P < .001).Atorvastatin treatment works for patients with carotid plaque by reducing LDL

2019 Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

152. Targeted metabolomic approach in men with carotid plaque. (Full text)

Targeted metabolomic approach in men with carotid plaque. The aim of the study was to analyse the presence of several metabolites related to atherosclerosis in the plasma of patients with unstable carotid plaque and in the plasma of healthy subjects.We included 20 patients who had undergone carotid endarterectomy and 20 healthy subjects as a control group. All the subjects recruited were male. We used a metabolomic approach with liquid chromatography coupled to mass spectrometry to evaluate (...) plasma metabolite levels in the metabolic pathway involved in the progression of atherosclerotic plaque.We observed that circulating levels of 20-HETE were significantly higher in patients with atheroma plaque than in healthy subjects (p = 0.018). No differences were found with regard to the other metabolites analysed. We also conducted a random forest analysis and found that 20-HETE was the main differentiator in the list of selected metabolites. In addition, plasma levels of 20-HETE correlated

2018 PLoS ONE PubMed

153. Effect of chewing an apple on dental plaque removal and on salivary bacterial viability. (Full text)

Effect of chewing an apple on dental plaque removal and on salivary bacterial viability. Studies on dental plaque removal by chewing an apple are scarce and dated, with conflicting findings. This study aimed to determine whether chewing an apple produced mechanical removal of dental plaque or had any effect on salivary bacterial viability.The study group consisted of 20 healthy adults with good oral health status who were randomly assigned to brush their teeth or eat an apple. After 2 weeks (...) , the experiment was repeated with the order reversed. Plaque index (PI) and the bacterial viability (BV) in a sample of whole saliva (spit) were determined before brushing or apple eating (baseline, B), immediately afterward (A) and 24 hours afterward (24).After chewing an apple, PI-A was significantly higher than both PI-B (P < .001) and PI-24 (P < .001). BV-A was significantly lower than BV-B (P < .001), with a return to baseline values at the BV-24 measurement.Chewing an apple does not remove dental plaque

2018 PLoS ONE PubMed

154. Tildrakizumab (Ilumetri) - plaque psoriasis

Tildrakizumab (Ilumetri) - plaque psoriasis Ilumetri | European Medicines Agency Search Search Menu Ilumetri tildrakizumab Table of contents Authorised This medicine is authorised for use in the European Union. Overview Ilumetri is a medicine that acts on the immune system and is used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease for whom treatments applied to the skin are not suitable. Ilumetri contains (...) the tildrakizumab. Expand section Collapse section How is Ilumetri used? Ilumetri can only be obtained with a prescription and should be used under the supervision of a doctor experienced in diagnosing and treating plaque psoriasis. Ilumetri is available as a solution in pre-filled syringes for injection under the skin. The recommended dose is one 100 mg injection, followed by a further dose after 4 weeks and then an injection every 12 weeks. The dose may be increased to 200 mg in certain patients, for example

2018 European Medicines Agency - EPARs

155. Tildrakizumab (Ilumya) - To treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Tildrakizumab (Ilumya) - To treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy Drug Approval Package: ILUMYA (tildrakizumab-asmn) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ILUMYA (tildrakizumab-asmn) Company: Merck Sharp & Dohme Corporation Application Number: 761067 Approval Date: 03/20/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2018 FDA - Drug Approval Package

156. Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Randomised Phase 2 Study. (PubMed)

Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Randomised Phase 2 Study. Inhibiting the interleukin (IL)-23 cytokine in patients with psoriasis has demonstrated high levels of skin clearance. In this Phase 2 (AMAF, NCT02899988), multicentre, double-blind trial, we investigated the efficacy and safety of three dose groups of mirikizumab (LY3074828), a p19-directed IL-23 antibody, compared to placebo in patients with moderate (...) -to-severe plaque psoriasis.Adult patients were randomised 1:1:1:1 to receive placebo (N=52), mirikizumab 30 mg (N=51), 100 mg (N=51), or 300 mg (N=51) subcutaneously at Weeks 0 and 8. The primary objective was to evaluate superiority of mirikizumab to placebo in achieving a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) response at Week 16. Comparisons were done using logistic regression analysis with treatment, geographic region and previous biologic therapy in the model. Missing

2019 British Journal of Dermatology

157. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. (Full text)

Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. The use of biologic therapy has increased over the past decade well beyond primary autoimmune diseases. Indeed, a recent trial using an anti-IL-1beta antibody reduced second myocardial infarction (MI) in those who have had MI. Psoriasis is a chronic inflammatory disease often treated with biologics when severe, is associated with increased risk of MI (...) , in part driven by high-risk coronary plaque phenotypes by coronary computed tomography angiography (CCTA). We hypothesized that we would observe a reduction in inflammatory-driven phenotypes of coronary plaque, including non-calcified coronary plaque burden and lipid-rich necrotic core in those treated with biologic therapy after one-year compared with non-biologic therapy.In a prospective, observational study, 290 participants were recruited from 1 January 2013 through 31 October 2018 with 215

2019 Cardiovascular Research PubMed

158. Gpihbp1 deficiency accelerates atherosclerosis and plaque instability in diabetic Ldlr<sup>-/-</sup> mice. (PubMed)

Gpihbp1 deficiency accelerates atherosclerosis and plaque instability in diabetic Ldlr-/- mice. Glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1) plays a crucial role in triglyceride hydrolysis, and GPIHBP1 deficiency leads to severe hypertriglyceridemia (HTG). Gpihbp1 knockout (GKO) mice develop mild lesions in the aortic root at the age of 11 months. Herein, we investigated the effect of Gpihbp1 deficiency on atherosclerosis (AS) under (...) the experiment.No atherosclerotic lesions were detected in the aorta in GKO mice after 4 months of diabetes. Compared with LKO mice, GLDKO mice manifested enhanced aortic atherosclerotic lesions, decreased plaque stability, and increased oxidative stress and inflammation in plaques at 3 and 5 months after diabetes. Atherosclerotic lesions in the coronary artery and dilated remodeling in the aortic root were also found in GLDKO diabetic mice.Gpihbp1 deficiency accelerates the development of AS in the aorta

2019 Atherosclerosis

159. Institute for Clinical and Economic Review (ICER) Psoriasis Update 2018: What it means for dermatologists treating moderate-to-severe plaque psoriasis. (PubMed)

Institute for Clinical and Economic Review (ICER) Psoriasis Update 2018: What it means for dermatologists treating moderate-to-severe plaque psoriasis. This paper aims to summarize the key findings of the updated report issued in August 2018 by the Institute of Clinical and Economic Review (ICER) regarding the clinical efficacy and budget impact of various immunomodulators.This paper specifically focuses on the inclusion of two new biologics, guselkumab and certolizumab in the context

2019 Journal of Dermatological Treatment

160. Dual roles of heparanase in human carotid plaque calcification. (PubMed)

Dual roles of heparanase in human carotid plaque calcification. Calcification is a hallmark of advanced atherosclerosis and an active process akin to bone remodeling. Heparanase (HPSE) is an endo-β-glucuronidase, which cleaves glycosaminoglycan chains of heparan sulfate proteoglycans. The role of HPSE is controversial in osteogenesis and bone remodeling while it is unexplored in vascular calcification. Previously, we reported upregulation of HPSE in human carotid endarterectomies from

2019 Atherosclerosis

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>